Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Key facts

Sponsor

Sun Yat-sen University

Intervention

Furmonertinib(drug)

Enrollment

280 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2028

Study locations (26)

• The First Hospital of Jilin University, Changchun, China
• Sichuan Provincial People's Hospital, Chengdu, China
• Dongguan People's Hospital, Dongguan, China
• Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital, Dongyang, China
• The First People's Hospital of Foshan, Foshan, China
• Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
• Nanfang Hospital, Southern Medical University, Guangzhou, China
• Sun Yat-sen University cancer center, Guangzhou, China
• The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
• The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
• The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
• Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China
• Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, China
• Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
• Mianyang Central Hospital, Mianyang, China
• +11 more locations on ClinicalTrials.gov

Collaborators

Allist Pharmaceuticals, Inc. · GeneCast Biotechnology Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Epidermal disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07222215
  PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  Kristina A. Fanucci
• RECRUITINGPHASE1NCT07214662
  A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
  Genentech, Inc.
• RECRUITINGPHASE1, PHASE2NCT07049055
  A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
  Engeneic Pty Limited
• RECRUITINGPHASE1NCT07361237
  A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
  Tongji University
• RECRUITINGPHASE2, PHASE3NCT07100080
  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT07216183
  Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1
  North Carolina State University
• RECRUITINGPHASE3NCT06982521
  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  Relay Therapeutics, Inc.
• RECRUITINGPHASE2NCT06348134
  Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
  University of Chicago

See all trials for Epidermal disease →